Who is popular today?

Yesterday, AIVITA Biomedical, Inc., a biotech company specialising in innovative cell applications, announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. Across both studies, AV-COVID-19 was well-tolerated with very few and low-grade adverse events. Single injections induced desirable antigen-specific T-cell responses in 94% of participants at 14 days and…